Two new indications for Gaviscon

The licence for Gaviscon Advance (sodium alginate, potassium bicarbonate) aniseed suspension has been extended.

It can now be used to treat of symptoms of gastro-oesophageal reflux during concomitant treatment with acid suppressing therapy and symptoms of laryngopharyngeal reflux.

View Gaviscon Advance drug record

Further information: Reckitt Benckiser

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...

Updated bowel disease treatment summaries published by MIMS

Updated bowel disease treatment summaries published by MIMS

Updated quick-reference summaries of the latest NICE...

Boys to be vaccinated against HPV from September

Boys to be vaccinated against HPV from September

The routine HPV vaccination programme is to be extended...